320 related articles for article (PubMed ID: 36412253)
1. RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020.
Packnett ER; Winer IH; Larkin H; Oladapo A; Gonzales T; Wojdyla M; Goldstein M; Smith VC
Hum Vaccin Immunother; 2022 Nov; 18(6):2140533. PubMed ID: 36412253
[TBL] [Abstract][Full Text] [Related]
2. Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29-34 wGA) infants without outpatient palivizumab administration.
Packnett ER; Winer IH; Oladapo A; Wojdyla M
Hum Vaccin Immunother; 2023 Aug; 19(2):2252289. PubMed ID: 37828711
[TBL] [Abstract][Full Text] [Related]
3. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
[TBL] [Abstract][Full Text] [Related]
4. Increasing Rates of RSV Hospitalization among Preterm Infants: A Decade of Data.
Kong AM; Winer IH; Zimmerman NM; Diakun D; Bloomfield A; Gonzales T; Fergie J; Goldstein M; Krilov LR
Am J Perinatol; 2023 Oct; 40(14):1529-1536. PubMed ID: 34704241
[TBL] [Abstract][Full Text] [Related]
5. Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017.
Fergie J; Goldstein M; Krilov LR; Wade SW; Kong AM; Brannman L
Hum Vaccin Immunother; 2021 May; 17(5):1536-1545. PubMed ID: 33090914
[TBL] [Abstract][Full Text] [Related]
6. SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
Anderson EJ; DeVincenzo JP; Simões EAF; Krilov LR; Forbes ML; Pannaraj PS; Espinosa CM; Welliver RC; Wolkoff LI; Yogev R; Checchia PA; Domachowske JB; Halasa N; McBride SJ; Kumar VR; McLaurin KK; Rizzo CP; Ambrose CS
Am J Perinatol; 2020 Mar; 37(4):421-429. PubMed ID: 30991438
[TBL] [Abstract][Full Text] [Related]
7. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants.
Krilov LR; Fergie J; Goldstein M; Brannman L
Am J Perinatol; 2020 Jan; 37(2):174-183. PubMed ID: 31430818
[TBL] [Abstract][Full Text] [Related]
8. Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016.
Goldstein M; Krilov LR; Fergie J; McLaurin KK; Wade SW; Diakun D; Lenhart GM; Bloomfield A; Kong AM
Am J Perinatol; 2018 Dec; 35(14):1433-1442. PubMed ID: 29920638
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants.
DeVincenzo JP; Ambrose CS; Makari D; Weiner LB
Hum Vaccin Immunother; 2016 Apr; 12(4):971-5. PubMed ID: 26889568
[TBL] [Abstract][Full Text] [Related]
10. Unintended Consequences Following the 2014 American Academy of Pediatrics Policy Change for Palivizumab Prophylaxis among Infants Born at Less than 29 Weeks' Gestation.
Goldstein M; Krilov LR; Fergie J; Brannman L; Wade SW; Kong AM; Ambrose CS
Am J Perinatol; 2021 Aug; 38(S 01):e201-e206. PubMed ID: 32299107
[TBL] [Abstract][Full Text] [Related]
11. Respiratory Syncytial Virus and All-Cause Bronchiolitis Hospitalizations Among Preterm Infants Using the Pediatric Health Information System (PHIS).
Fergie J; Suh M; Jiang X; Fryzek JP; Gonzales T
J Infect Dis; 2022 Apr; 225(7):1197-1204. PubMed ID: 32691037
[TBL] [Abstract][Full Text] [Related]
12. Real-World Studies of Respiratory Syncytial Virus Hospitalizations among Moderate/Late Preterm Infants Exposed to Passive Immunoprophylaxis with Palivizumab.
Manzoni P; Baraldi E; Luna MS; Tzialla C
Am J Perinatol; 2022 Dec; 39(S 01):S7-S13. PubMed ID: 36307092
[TBL] [Abstract][Full Text] [Related]
13. A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.
Keary IP; Ravasio R; Fullarton JR; Manzoni P; Lanari M; Paes BA; Carbonell-Estrany X; Baraldi E; Tarride JÉ; Rodgers-Gray B
PLoS One; 2023; 18(8):e0289828. PubMed ID: 37561741
[TBL] [Abstract][Full Text] [Related]
14. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
[TBL] [Abstract][Full Text] [Related]
15. Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.
Ambrose CS; Anderson EJ; Simões EA; Wu X; Elhefni H; Park CL; Sifakis F; Groothuis JR
Pediatr Infect Dis J; 2014 Jun; 33(6):576-82. PubMed ID: 24622396
[TBL] [Abstract][Full Text] [Related]
16. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study.
Priante E; Tavella E; Girardi E; Militello MA; Mardegan V; Maule MM; Dall'Agnola A; Baraldi E; Manzoni P
Am J Perinatol; 2019 Jul; 36(S 02):S77-S82. PubMed ID: 31238365
[TBL] [Abstract][Full Text] [Related]
17. Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants.
Staebler S; Blake S
Policy Polit Nurs Pract; 2021 Feb; 22(1):41-50. PubMed ID: 33050785
[TBL] [Abstract][Full Text] [Related]
18. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.
McLaurin KK; Farr AM; Wade SW; Diakun DR; Stewart DL
J Perinatol; 2016 Nov; 36(11):990-996. PubMed ID: 27490190
[TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics.
Krilov LR; Anderson EJ
J Perinatol; 2020 Aug; 40(8):1135-1144. PubMed ID: 32499597
[TBL] [Abstract][Full Text] [Related]
20. Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan.
Chi H; Chung CH; Lin YJ; Lin CH
PLoS One; 2018; 13(5):e0197410. PubMed ID: 29746578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]